Glenmark Pharmaceuticals has received final approval from the U.S. Food and Drug Administration (US FDA) for its Fluticasone Propionate Inhalation Aerosol USP, 44 mcg per actuation, marking a significant step in expanding the company’s respiratory drug portfolio in the United States.
The approval was granted to Glenmark Specialty SA, the company’s subsidiary, enabling the launch of a generic version of the widely used respiratory medication.
Equivalent to Widely Used Reference Drug
The US FDA confirmed that Glenmark’s inhalation aerosol is bioequivalent and therapeutically equivalent to the reference listed drug Flovent HFA, which is marketed by GlaxoSmithKline.
Flovent HFA is commonly prescribed for the management of respiratory conditions such as asthma. With this approval, Glenmark will be able to introduce a more cost-effective generic alternative while maintaining the same standards of safety and effectiveness as the original medication.
Exclusive Market Opportunity
The product has also been granted Competitive Generic Therapy (CGT) designation, which provides certain regulatory benefits.
As the first approved applicant under the relevant provisions of the Federal Food, Drug, and Cosmetic Act, Glenmark will receive 180 days of CGT exclusivity once the product is commercialised. During this period, competing generic versions cannot enter the market, giving the company a temporary competitive advantage.
Commercial Launch Planned for March 2026
Distribution of the medication in the United States will be handled by Glenmark Pharmaceuticals Inc., with the product expected to launch in March 2026.
According to data from IQVIA, the Flovent HFA 44 mcg inhalation aerosol market generated approximately $520.1 million in sales in the 12 months ending January 2026, indicating a significant commercial opportunity for Glenmark.
Company Statement
Commenting on the development, Marc Kikuchi, President and Business Head for North America at Glenmark, said the approval represents an important milestone in expanding the company’s respiratory therapy portfolio in the US.
He noted that the CGT designation and first-applicant status highlight the company’s technical expertise in developing complex inhalation therapies and reaffirm its commitment to improving access to affordable respiratory treatments for patients and healthcare providers.
Summary:
Glenmark Pharmaceuticals has received US FDA approval for Fluticasone Propionate Inhalation Aerosol USP (44 mcg), a generic equivalent of Flovent HFA. The product will be launched in the US in March 2026 and has been granted 180 days of Competitive Generic Therapy exclusivity, giving Glenmark a temporary market advantage. The approval strengthens the company’s respiratory portfolio and opens access to a market valued at over $520 million annually.
This article is intended solely for educational and informational purposes. The securities or companies mentioned are provided as examples and should not be considered as recommendations. Nothing contained herein constitutes personal financial advice or investment recommendations. Readers are advised to conduct their own research and consult a qualified financial advisor before making any investment decisions.
Investments in securities markets are subject to market risks. Please read all related documents carefully before investing.